Association between development of hypothyroidism and improved survival in patients with head and neck cancer

Archives of Otolaryngology - Head and Neck Surgery

Volumn 132, Issue 10, 2006, Pages 1041-1046

  Nelson, Marc ^a   Hercbergs, Aleck ^a   Rybicki, Lisa ^a   Strome, Marshall ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THYROTROPIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPOTHYROIDISM; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PROPORTIONAL HAZARDS MODEL; SQUAMOUS CELL CARCINOMA;

FEMALE; HUMANS; HYPOTHYROIDISM; MALE; MIDDLE AGED; OTORHINOLARYNGOLOGIC NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; SURVIVAL RATE;

EID: 33750162642     PISSN: 08864470     EISSN: 08864470     Source Type: Journal    
DOI: 10.1001/archotol.132.10.1041     Document Type: Article

References (23)

1. Franklyn JA, Maisonneuve P, Sheppard M, et al. Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet. 1999;353:2111-2115.
2. Goldman MB, Monson RR, Maloof F. Benign thyroid diseases and the risk of death from breast cancer. Oncology. 1992;49:461-466.
3. Hercbergs A, Leith JT. Spontaneous remission of metastatic lung cancer following myxedema coma - an apoptosis-related phenomenon? J Natl Cancer Inst. 1993;85:1342-1343.
4. Hercbergs A. Spontaneous remission of cancer - a thyroid hormone dependent phenomenon? Anticancer Res. 1999;19:4839-4844.
5. Atkins MB, Mier JW, Parkinson DR, et al. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med. 1988;318:1557-1563.
6. Reid I, Sharpe I, McDevitt J, et al. Thyroid dysfunction can predict response to immunotherapy with interleukin-2 and interferon-2α. Br J Cancer. 1991;64:915-918.
7. Weijl NI, Van Der Harst D, Brand A, et al. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. J Clin Oncol. 1993;11:1376-1383.
8. Hercbergs A. Thyroid disease/hypothyroidism correlates positively with survival in patients with metastatic renal cell cancer. Proc Am Assoc Cancer Res. 1998;39:482.
9. Hercbergs A, Werner A, Brenner HJ. Does hypothyroidism favor the response to therapy in metastatic breast cancer [abstract]? Proc ASCO. 1988;7:A77.
10. Mishkin SY, Pollak R, Yalovsky MA, et al. Inhibition of local and metastatic hepatoma growth and prolongation of survival after induction of hypothyroidism. Cancer Res. 1981;41:3040-3045.
11. Kumar MS, Chiang T, Deodhar SD. Enhancing effect of thyroxine on tumor growth and metastases in syngeneic mouse tumor systems. Cancer Res. 1979;39:3515-3518.
12. Shoemaker JP, Bradley RL, Hoffman RV. Increased survival and inhibition of mammary tumors in hypothyroid mice. J Surg Res. 1976;21:151-154.
13. Jetten AM, Vollberg TM, Nervi C, et al. Positive and negative regulation of proliferation and differentiation in tracheobronchial epithelial cells. Am Rev Respir Dis. 1990;142:S36-S39.
14. Stahlman MT, Gray ME, Chytil F, et al. The effect of retinol on fetal lamb tracheal epithelium with and without epidermal growth factor: a model for the effect of retinol on the healing lung of human premature infants. Lab Invest. 1988;59:25-35.
15. Humes HD, Cieslinski DA, Johnson LB, et al. Triiodothyronine enhances renal tubule cell replication by stimulating EGF receptor gene expression. Am J Physiol. 1992;262:F540-F545.
16. DeFesi CR, Fels EC, Surks MI. L-Triiodothyronine (T3) stimulates growth of cultured GC cells by action early in the G1 period: evidence for mediation by the nuclear T3 receptor. Endocrinology. 1985;116:2062-2069.
17. Bhat MK, Yu C, Yap N, et al. Tumor suppressor p53 is a negative regulator in thyroid hormone receptor signaling pathways. J Biol Chem. 1997;272:28989-28993.
18. Cayrol C, Knibiehler M, Ducommun B. p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene. 1998;16:311-320.
19. Toms SA, Hercbergs A, Liu J, et al. Thyroid hormone depletion inhibits astrocytoma proliferation via induction of p21 (WAF1/CIP1). Anticancer Res. 1998;18:289-294.
20. Cheng SY, Hasumura S, Willingham MC, et al. Purification and characterization of a membrane-associated 3,3′,5-triiodo-L-thyronine binding protein from a human carcinoma cell line. Proc Natl Acad Sci U S A. 1986;83:947-951.
21. Xiao Q, Nikodem VM. Apoptosis in the developing cerebellum of the thyroid hormone deficient rat. Front Biosci. 1998;3:A52-A57.
22. Hercbergs AA, Suh JH, Lee S, et al. Propylthiouracil-induced chemical hypothyroidism with high dose tamoxifen prolongs survival with increased response rate in recurrent high-grade glioma. Anticancer Res. 2003;23:617-626.
23. Escobar-Morreale HF, Escobar del Ray F, Obregon MJ, et al. Only the combined treatment with thyroxine and triiodothyronine ensures euthyroidism in all tissues of the thyroidectomized rat. Endocrinology. 1996;137:2490-2502.